Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in ...

CEO Tal Zaks shares Exsilio’s origin story and the exciting science that convinced him to helm the nascent biotech.

Exsilio Therapeutics CEO and OrbiMed partner Tal Zaks on how he shows investors the value path for cutting-edge research.

Managing clinical trial disclosures can be tedious and error-prone, opening the door to noncompliance. TrialScope Disclose provides a better way. Our centralized platform automates data entry and ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Revolo Biotherapeutics’ pipeline is focusing on creating a commercially viable subcutaneous dosage form for its lead candidate while working on a sublingual solution that is even more patient friendly ...

Since 2008, PCM Trials has led the way in mobile research. Our Certified Mobile Research Nurses (CMRNs) are driving the shift to patient-centric, decentralized clinical trials, giving individuals the ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski discuss their companies’ partnership, Life’s pipeline, and Columbus’ biotech hub.

Foresite Labs' Vik Bajaj, Ph.D. shares how massive data sets are essential to shortening drug development timelines and creating innovative therapeutics.

Revolo’s plans for 2025 include expanding clinical trials for its lead eosinophilic esophagitis candidate and developing a sublingual delivery method.